田上 瑞記 (タガミ ミズキ)

TAGAMI Mizuki

写真a

機関リポジトリを検索

職名

講師

研究室所在地

阿倍野キャンパス

プロフィール

1997年 兵庫県立神戸高等学校卒業
2004年 藤田保健衛生大学医学部卒業
2004年 神戸労災病院初期臨床研修医
2005年 神戸大学医学部附属病院初期臨床研修医
2006年 神戸大学医学部附属病院眼科専攻医
2010年 神戸大学医学部眼科特定助教
2011年 神戸大学大学院外科系講座眼科学修了(医学博士)
2011年 ジョンズホプキンス大学ウィルマー眼研究所
2012年 三菱神戸病院医員
2013年 神戸海星病院眼科医長
2018年 神戸海星病院眼科部長

取得学位 【 表示 / 非表示

  • 神戸大学 -  医学博士

研究分野 【 表示 / 非表示

眼科学

研究概要 【 表示 / 非表示

  • 眼腫瘍 眼炎症 網膜硝子体手術

現在の職務 【 表示 / 非表示

  • 大阪市立大学   医学研究科   臨床医科学専攻   講師  

出身大学院 【 表示 / 非表示

  •  
     
     

    神戸大学  医学研究科  博士課程

出身学校 【 表示 / 非表示

  • 1998年04月
    -
    2004年03月

    藤田保健衛生大学  医学部 

 

論文 【 表示 / 非表示

  • Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva

    Harada Naonori, Tagami Mizuki, Koh Hideo, Ohsawa Masahiko, Hino Masayuki, Nakamae Hirohisa

    INTERNATIONAL JOURNAL OF HEMATOLOGY  114 ( 4 ) 413 - 414 2021年10月  [査読有り]

    DOI PubMed

  • Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival

    Tagami Mizuki, Kakehashi Anna, Sakai Atsushi, Misawa Norihiko, Katsuyama-Yoshikawa Atsuko, Wanibuchi Hideki, Azumi Atsushi, Honda Shigeru

    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY  2021年05月  [査読有り]

     概要を見る

    PURPOSE: Conjunctival squamous cell carcinoma (SCC) is primarily treated with surgical resection. SCC has various stages, and local recurrence is common. The purpose of this study was to investigate thrombospondin-1 expression and its association with prognosis. METHODS: In this retrospective study, a gene expression array along with immunohistochemistry were performed for the evaluation of thrombospondin-1 expression, localization, as well as Ki67 labeling cell indices in carcinoma in situ (Tis) and advanced conjunctival SCC (Tadv). The presence or absence and intensity of cytoplasmic and nuclear staining in tumor cells were also divided into groups with a score of 0-3 and semi-quantitatively analyzed to investigate intracellular staining patterns. The association between thrombospondin-1 expression and tumor progression in a series of 31 conjunctival SCCs was further investigated. RESULTS: All 31 patients in the cohort (100%) were East Asian. A simple comparison between Tis and Tadv demonstrated significant differences in expressions of 45 genes, including thrombospondin-1 (p < 0.01). In this cohort, 30/31 tumors were positive (96%) for thrombospondin-1. Furthermore, thrombospondin-1 intracellular staining pattern analysis scores were 2.12 and 0.96 for nuclear and cytoplasmic staining, respectively, with a significant difference observed between Tis and Tadv (p < 0.01). Alteration of the Ki67 labeling index was significantly correlated with that of the thrombospondin-1 cytoplasmic score (p = 0.030). Furthermore, univariate Cox regression analysis showed a significant correlation between thrombospondin-1 staining and progression-free survival (p = 0.026) and final orbital exenteration (p = 0.019). CONCLUSIONS: The present results demonstrated that thrombospondin-1 is a potential molecular target in the pathology of conjunctival SCC, in addition to serving as a prognostic factor.

    DOI PubMed

  • Two Cases of Extremely High-IL-6 Pan-uveitis with Subretinal Exudation and Cell Migration

    Tagami Mizuki, Misawa Norihiko, Sakai Atsushi, Honda Shigeru

    OCULAR IMMUNOLOGY AND INFLAMMATION    1 - 5 2021年04月  [査読有り]

     概要を見る

    Purpose: To describe two cases of extremely high-IL-6 pan-uveitis with subretinal exudation and cell migration.Methods: Pre-operative and postoperative images and IL-6 values in vitreous samples of two pan-uveitis cases were analyzed.Results: Case 1 was a 76-year-old man with blurry vision in his right eye. Fundus examination and optical coherence tomography showed vitreous opacification with vitreous cells and the presence of a white-yellowish retinal exudate with peripheral choroidal detachment all around. The IL-6 value was 16,600 pg/ml. Case 2 was a 63-year-old man with blurry vision in his right eye. On fundus examination, there was severe vitreous opacification in his right eye. The IL-6 value was 26,600 pg/ml. Importantly, there was good responsiveness to steroids and the TNF inhibitor.Conclusion: Unclassified intraocular inflammation might include a new category of disease with unilateral pan-uveitis with good response to steroid therapy and extremely high vitreous IL-6 values.

    DOI PubMed

  • Clinical benefit for clinical sequencing using cancer panel testing

    Nishimura Sadaaki, Sugimoto Atsushi, Kushiyama Shuhei, Togano Shingo, Kuroda Kenji, Yamamoto Yurie, Yamauchi Makoto, Sumi Toshiyuki, Kaneda Hiroyasu, Kawaguchi Tomoya, Kato Minoru, Tagami Mizuki, Oebisu Naoto, Hoshi Manabu, Kimura Kenjiro, Kubo Shoji, Muguruma Kazuya, Takashima Tsutomu, Ohira Masaichi, Yashiro Masakazu

    PLOS ONE  16 ( 2 ) e0247090 2021年02月  [査読有り]

     概要を見る

    BACKGROUND: Clinical sequencing using a panel of genes has recently been applied worldwide for patients with refractory solid tumors, but the significance of clinical sequencing using gene panel testing remains uncertain. Here we sought to clarify the feasibility and utility of clinical sequencing in the treatment of refractory tumors at our hospital. METHODS: A total of 39 patients with advanced solid tumors treated at our hospital between 2018 and 2020 were enrolled in the clinical sequencing. Among them, we identified 36 patients whose tissue samples were of suitable quality for clinical sequencing, and we analyzed the genomic profiles of these tumors. RESULTS: Pathogenic alterations were detected in 28 (78%) of the 36 patients. The most common mutation was TP53 (55%), followed by KRAS (22%), and the highest frequency of gene amplification was ERBB2 (17%). Nine of the 36 patients were identified as candidates for novel molecular-targeted therapy based on their actionable gene alterations, but only one case ended up receiving novel targeted therapy following the genetic tests. CONCLUSIONS: Our current results suggested that clinical sequencing might be useful for the detection of pathogenic alterations and the management of additional cancer treatment. However, molecular target based on actionable genomic alteration does not always bridge to subsequent therapy due to clinical deterioration, refusal for unapproved drug, and complexity of clinical trial access. Both improved optimal timing of clinical sequencing and a consensus about its off-label use might help patients receive greater benefit from clinical sequencing.

    DOI PubMed

  • Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment

    Sakai Atsushi, Tagami Mizuki, Kakehashi Anna, Katsuyama-Yoshikawa Atsuko, Misawa Norihiko, Wanibuchi Hideki, Azumi Atsushi, Honda Shigeru

    PLOS ONE  15 ( 8 ) e0238120 2020年08月  [査読有り]

     概要を見る

    PURPOSE: Conjunctival squamous cell carcinoma (SCC) is primarily treated with surgical resection. SCC has various stages, and local recurrence is common. The purpose of this study was to determine molecular localization of epidermal growth factor receptor (EGFR) and the possibility of EGFR as a biomarker for the management of conjunctival SCC. METHODS: In this retrospective study, we performed immunohistochemistry to evaluate EGFR expression and localization in tumor cells, EGFR mutation-specific expression (E746-A750del and L858R), and human papillomavirus expression in a series of 29 conjunctival SCCs. RESULTS: All 29 tumors in our cohort were EGFR positive (100%). Twenty-one of 29 tumors (72%) showed focal EGFR staining, and seven (28%) showed diffuse EGFR staining. In addition, we calculated the percentages of the two most important mutations in EGFR (exon 19 746-A750del (8/29, 27.5%), exon 21 (L858R mutant (2/29, 6.8%)) in conjunctival SCCs. We observed that the translocation of EGFR from the membrane into the cytoplasm was related to clinical prognosis, as we detected correlations between EGFR cytoplasmic staining and final orbital exenteration and between decreased EGFR membrane staining and progression-free survival. CONCLUSIONS: EGFR is important in the pathology of ocular surface squamous neoplasia including SCC and is a prognostic factor. Increased understanding of EGFR mutations may have important implications for future treatment options.

    DOI PubMed

全件表示 >>

その他記事(Misc) 【 表示 / 非表示

講演・口頭発表等 【 表示 / 非表示

全件表示 >>